Results 21 to 30 of about 14,491 (226)
Integrating analytical quality by design into bioanalytical method development: an HPLC-FLD method for quantification of alectinib in biological matrix. [PDF]
BMC ChemThis study presents the development and validation of a fluorescence-based high-performance liquid chromatography (HPLC) method for the quantification of alectinib in rat plasma, with a focus on the application of Analytical Quality by Design (AQbD) to ...
Lee EJ, Koo N, Kim MJ, Lee KR, Chae YJ.
europepmc +2 more sources
A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]
, 2017 A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj +9 more
core +1 more source
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2017 Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK‐positive non–small‐cell lung cancer (NSCLC).
S. Peters +16 more
semanticscholar +1 more source
Magnesium Isoglycyrrhizinate Alleviates Alectinib-Induced Hepatotoxicity by Inhibiting Mitochondrial Damage-Mediated Pyroptosis. [PDF]
Drug Des Devel TherIntroduction Alectinib is a widely used first-line ALK inhibitor for fusion-positive non-small cell lung cancer. However, its clinical use is limited by hepatotoxicity, and its mechanism remains unclear. This study aims to elucidate how alectinib induces
Chen Y +10 more
europepmc +2 more sources
Thoracic Cancer, 2022 This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid
Ji Eun Park +3 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect.
Xianmeng Chen +5 more
doaj +1 more source
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. [PDF]
, 2017 Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved
Bivona, Trever G +2 more
core +3 more sources
SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]
, 2018 Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric +10 more
core +4 more sources
PLoS ONE, 2020 The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting.
Marine Sivignon +3 more
doaj +1 more source
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
Surgical Case Reports, 2018 Background Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer ...
Naoko Imanishi +6 more
doaj +1 more source